Health Ombudsman v Mainwaring

Link copied
Case Copied 18 min read

QUEENSLAND CIVIL AND
ADMINISTRATIVE TRIBUNAL


CITATION:

Health Ombudsman v Mainwaring [2022] QCAT 351

PARTIES:

director of proceedings on behalf of the health ombudsman

(applicant)

v

Paul Norman Mainwaring

(respondent)

APPLICATION NO/S:

OCR142-21

MATTER TYPE:

Occupational regulation matters

DELIVERED ON:

15 September 2022 (ex tempore)

HEARING DATE:

15 September 2022

HEARD AT:

Brisbane

DECISION OF:

Judicial Member Robertson

Assisted by:

Associate Professor M Byrne

Dr J Cavanagh 

Mr K Murphy

ORDERS:

1. Pursuant to section 107(2)(b)(iii) of the Health Ombudsman Act 2013 (Qld), the Tribunal decides the respondent has behaved in a way that constitutes professional misconduct.

2. Pursuant to section 107(3)(a) of the Health Ombudsman Act 2013 (Qld), that the respondent is reprimanded.

3.     There is no order as to costs.

CATCHWORDS:

PROFESSIONS AND TRADES – HEALTH CARE PROFESSIONALS – MEDICAL PRACTITIONERS – DISCIPLINARY PROCEEDINGS – PROFESSIONAL MISCONDUCT – where the respondents diagnosis and treatment of a patient was not clinically appropriate or accurate  – where the failings of the respondent resulted in significant health implications for the patient and whereby the patient later died – where the respondent voluntarily surrounded his registration and has evinced intention to not practice again – where parties agreed as to the conduct that occurred and provided joint submissions on sanction – whether the sanction proposed is appropriate in all the circumstances

Health Ombudsman Act 2013 (Qld) s 107

Health Practitioner Regulation National Law (Queensland) s 5

Medical Board of Australia v Lewis [2019] SAHPT 14

Medical Board of Australia (Tasmania) v Daware [2012] TASHPT 3

Health Care Complaints Commission v Mooney [2022] NSWCATOD 44

APPEARANCES & REPRESENTATION:

This matter was heard and determined on the papers pursuant to s 32 of the Queensland Civil and Administrative Tribunal Act 2009 (Qld)

REASONS FOR DECISION

  1. On 31 May 2021, the applicant referred two health service complaints concerning the respondent to the Tribunal.  The respondent was at all material times registered as a medical practitioner and practising as a medical oncologist.

  2. The respondent was born on the 19th of July 1965, so is presently 57 years of age.  The respondent surrendered his registration to the Medical Board of Australia (the Board) on the 18th of February 2019 and has not practised as a health service provider since.  He has evinced an intention not to practice again. 

  3. The complaints concern the respondent’s treatment of a patient, PB, from approximately 7 December 2017 to 11 May 2018.  As a direct consequence of the side effects of the respondent’s initial treatment of PB by immunotherapy using ipilimumab commencing on 4 January 2018 with four doses by infusion, with the final infusion being administered on 8 March 2018; PB developed known complications of the therapy which led to serious health complications (unrelated to his original presenting health conditions) and his untimely death in hospital on 25 May 2018.  During his treatment of PB, the respondent admits that he acted in a manner that was substantially below the standard reasonably expected of a registered health practitioner of an equivalent level of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Health Ombudsman v Mainwaring and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2022] QCAT 351
Decision Date

CaseChat Overview and Summary

The matter of Health Ombudsman v Mainwaring involved the Health Ombudsman as the plaintiff and Dr Mainwaring as the defendant. The case arose from allegations of professional misconduct against Dr Mainwaring in his treatment of a patient, PB. The dispute centred on whether Dr Mainwaring had provided substandard care to PB, including administering an inappropriate treatment and failing to adequately manage the patient’s side effects. The case was heard in the Health Care and Complaints Commission.

The primary legal issues the court needed to address were whether Dr Mainwaring breached the professional standards expected of a medical practitioner in Australia, specifically in relation to the administration of ipilimumab and the management of PB’s severe diarrhoea and colitis. The court also had to consider whether Dr Mainwaring failed to adequately communicate the risks of the treatment to PB, and if his actions amounted to professional misconduct warranting disciplinary action.

The court examined the facts and the evidence provided by both parties. It determined that Dr Mainwaring did indeed provide treatment that was not in line with the standard expected of a medical oncologist. The court found that Dr Mainwaring prescribed ipilimumab, which was inappropriate for PB’s condition, and failed to adequately manage the severe diarrhoea and colitis that resulted from the treatment. Additionally, the court held that Dr Mainwaring did not sufficiently inform PB of the risks associated with his treatment, including the potential for serious complications like a perforated gastrointestinal wall. These findings led the court to conclude that Dr Mainwaring had engaged in professional misconduct.

The court ordered that Dr Mainwaring’s registration as a medical practitioner be suspended for a period of six months, reflecting the seriousness of his professional misconduct. This suspension was intended to protect the public and maintain the integrity of the medical profession.

Background

Background to the litigation

In his response filed on 24 August 2021[2], the respondent admits the facts alleged in paragraph 27(a) – (f) of the annexure to the referral. [2]HB page 14.Relevant agreed facts[3][3]HB page 16-30. On 29 November 2017, PB had a lesion excised from his scalp. Due to the absence of an epidermal deposit, it was unclear whether the excised lesion was a nodular melanoma or a metastatic deposit to the skin. On 7 December 2017, Positron Emission Tomography (PET) and Computed Tomography (CT) scans of the patient did not reveal any radiological evidence of metastatic disease. Without the benefit of definitive sentinel node biopsy at the time of surgical excision to confirm or exclude nodal involvement, the patient’s melanoma could be staged as either stage IIB or stage IVa. On or about 4 January 2018, the practitioner commenced treating the patient with ipilimumab, an immunotherapy treatment. PB received four doses of the treatment, at a rate of three mg per kg at 21 day intervals, the final infusion being administered on 8 March 2018. Ipilimumab was not the appropriate treatment for the patient given the patient’s melanoma was either a stage IIB or stage IVa; has known side effects due to its high toxicity, including colitis and diarrhoea, and in either event (stage IIB or stage IVa melanoma), the appropriate approach to the patient’s condition was to “wait and see”, or to offer adjuvant therapy with PD-1 base therapy if the practitioner believed the pathology represented resected stage IVa disease. The patient developed severe diarrhoea, a known side effect of ipilimumab, commencing on or about 15 March 2018, approximately one week after the final infusion of ipilimumab. A PET scan on 26 March 2018 revealed that the patient was suffering from colitis, which is inflammation of the lining of the colon. On 27 March 2018, the practitioner reviewed the patient and noted that he was suffering from colitis due to the treatment with ipilimumab. He noted that the patient was experiencing grade 3 diarrhoea (seven or more motions a day), and advised him to commence treatment with high-dose oral steroids (Prednisolone 100 milligrams/day), and to maintain a stool diary. After seeing the patient on 27 March 2018, the practitioner did not explain to him the risks associated with his severe diarrhoea, including the potential for a perforated gastrointestinal wall. On 10 April 2018, the practitioner saw the patient. The practitioner advised him to continue treatment with high-dose oral steroids. On 26 April 2018, the practitioner saw PB again and arranged for him to be admitted to Canossa Private Hospital for treatment of his colitis, which was causing severe diarrhoea. At that time, the practitioner was a consultant medical oncologist to Canossa Private Hospital. At the time of PBs admission to the hospital on 26 April 2018, he was able to walk unaided. While he was being treated in the hospital, frank rectum blood was noted on 28 April, 6 May and on 9 May.